Areas of Focus
- Pathogenic Microbial Immunity
- Vaccines
- Antibody Engineering
Work Experience
- 2021-11~Present - Institute of Microbiology, Chinese Academy of Sciences - Researcher
- 2020-09~Present - Institute of Microbiology, Chinese Academy of Sciences - Young Research Group Leader
- 2017-01~2020-08 - Beijing Institute of Life Sciences, Chinese Academy of Sciences - Associate Researcher
- 2014-06~2016-12 - Beijing Institute of Life Sciences, Chinese Academy of Sciences - Assistant Researcher
- 2010-04~2014-04 - Technische Universität München - Ph.D
- 2009-09~2010-04 - Helmholtz Zentrum München - Research Assistant
- 2006-09~2009-07 - Graduate School of the Chinese Academy of Sciences, Institute of Microbiology, Chinese Academy of Sciences - M.Sc
- 2002-09~2006-07 - Wuhan University, School of Life Sciences - B.Sc
Academic Background & Achievements
- 2010-04--2014-04 Ph.D: Technische Universität München
- 2006-09--2009-07 M.Sc: Graduate School of the Chinese Academy of Sciences, Institute of Microbiology, Chinese Academy of Sciences
- 2002-09--2006-07 B.Sc: Wuhan University, School of Life Sciences
Publications
- Omicron neutralisation: RBD-dimer booster versus BE.7 and BA.5.2 breakthrough infection., Not mentioned, 2023
- A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5, Not mentioned, 2023
- Inside-out assembly of viral antigens for the enhanced vaccination, Not mentioned, 2023
- Dosing interval regimen shapes potency and breadth of antibody repertoire after vaccination of SARS-CoV-2 RBD protein subunit vaccine, Not mentioned, 2023
- Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2, Not mentioned, 2022
- Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults, Not mentioned, 2022
- Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines, Not mentioned, 2022
- Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults, Not mentioned, 2022
- 新药导读：新冠病毒蛋白亚单位疫苗, Not mentioned, 2022
- mRNA vaccines expressing homo-prototype/Omicron anchetero-chimeric RBD-dimers against SARS-CoV-2, Not mentioned, 2022
- Protective Zika vaccines engineered to eliminate enhancement of dengue infection via immunodominance switch, Not mentioned, 2021
- Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials, Not mentioned, 2021
- Avian influenza A(H7N9) virus: from low pathogenic to highly pathogenic, Not mentioned, 2021
- Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants, Not mentioned, 2021
- Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19, Not mentioned, 2021
- Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection, Not mentioned, 2021
- Protective Zika vaccines engineered to eliminate enhancement of dengue infection via immunodominance switch, Not mentioned, 2021
- Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2, Not mentioned, 2021
- Viral targets for vaccines against COVID-19, Not mentioned, 2021
- Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021, Not mentioned, 2021
- Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials, Not mentioned, 2021
- A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS, Not mentioned, 2020
- A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS, Not mentioned, 2020
- A universal design of betacoronavirus vaccines against COVID-19, MERS and SARS, Not mentioned, 2020
- Molecular Basis of a Protective/Neutralizing Monoclonal Antibody Targeting Envelope Proteins of both Tick-Borne Encephalitis Virus and Louping Ill Virus, Not mentioned, 2019
- Human Neonatal Fc Receptor Is the Cellular Uncoating Receptor for Enterovirus B, Not mentioned, 2019
- Double Lock of a Human Neutralizing and Protective Monoclonal Antibody Targeting the Yellow Fever Virus Envelope, Not mentioned, 2019
- Recombinant Chimpanzee Adenovirus Vaccine AdC7-M/E Protects against Zika Virus Infection and Testis Damage, Not mentioned, 2018
- Molecular Basis of Antibody-Mediated Neutralization and Protection Against Flavivirus, Not mentioned, 2016
- Structures of the Zika Virus Envelope Protein and Its Complex with a Flavivirus Broadly Protective Antibody, Not mentioned, 2016
- Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus, Not mentioned, 2016
- Modified Vaccinia Virus Ankara Triggers Type I IFN Production in Murine Conventional Dendritic Cells via a cGAS/STING-Mediated Cytosolic DNA-Sensing Pathway, Not mentioned, 2014
- Diverse Peptide Presentation of Rhesus Macaque Major Histocompatibility Complex Class I Mamu-A*02 Revealed by Two Peptide Complex Structures and Insights into Immune Escape of Simian Immunodeficiency Virus, Not mentioned, 2011
- 恒河猴MHC-I类分子Mamu-A*02与猴免疫缺陷病毒抗原表位复合物的纯化和晶体学分析, Not mentioned, 2009
- 三种食品致突能力的研究, Not mentioned, 2005
- Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants, Not mentioned
Awards
- Chinese Academy of Sciences Youth Innovation Promotion Association 'Outstanding Member' (2022)
- 6th Zhongyuan Concord Life Medicine Innovation Breakthrough Award (2021)
- Chinese Academy of Sciences Youth Promotion Association Member (2018)
- 8th Young Scholar Award of the Chinese Society for Immunology (2018)
- Zeping Excellent Paper Award (2017)
- Tengquan Cup Excellent Paper Award (2016)
